Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin
暂无分享,去创建一个
A. Weng | C. Görick | H. Fuchs | M. Thakur | Cheenu Bhargava | Nicole Niesler | R. Gilabert-Oriol | K. Haussmann
[1] Ł. Pecio,et al. Highly Polar Triterpenoid Saponins from the Roots of Saponaria officinalis L , 2016 .
[2] M. Melzig,et al. Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent , 2015, Immunopharmacology and immunotoxicology.
[3] M. Melzig,et al. Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy , 2014, Current pharmaceutical design.
[4] I. Jacobs,et al. Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey , 2014, Pharmaceuticals.
[5] B. Wiesner,et al. Reporter Assay for Endo/Lysosomal Escape of Toxin-Based Therapeutics , 2014, Toxins.
[6] I. Pastan,et al. Immunotoxins for leukemia. , 2014, Blood.
[7] G. Marti,et al. Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. , 2013, American journal of clinical pathology.
[8] T. Hug,et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. , 2013, Molecular pharmaceutics.
[9] B. Wiesner,et al. Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge. , 2013, International journal of biological macromolecules.
[10] L. Polito,et al. Saporin-S6: A Useful Tool in Cancer Therapy , 2013, Toxins.
[11] A. Weng,et al. Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression. , 2013, Protein expression and purification.
[12] M. Melzig,et al. Real-time analysis of membrane permeabilizing effects of oleanane saponins. , 2013, Bioorganic & medicinal chemistry.
[13] M. Melzig,et al. Saponins modulate the intracellular trafficking of protein toxins. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[14] M. Melzig,et al. The toxin component of targeted anti‐tumor toxins determines their efficacy increase by saponins , 2012, Molecular oncology.
[15] Mayank Thakur,et al. Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement. , 2012, Biosensors & bioelectronics.
[16] M. Melzig,et al. Triterpenoid saponins of the Caryophyllaceae and Illecebraceae family , 2010 .
[17] P. Schmieder,et al. A convenient method for saponin isolation in tumour therapy. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[18] Mitchell R. Smith,et al. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. , 2010, P & T : a peer-reviewed journal for formulary management.
[19] M. Czuczman,et al. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms , 2010, Immunologic research.
[20] I. Pastan,et al. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.
[21] G. Packham,et al. Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling* , 2008, Journal of Biological Chemistry.
[22] P. Greenberg,et al. Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1 , 2008, The Journal of Immunology.
[23] G. Mazza,et al. Saponins: Properties, Applications and Processing , 2007, Critical reviews in food science and nutrition.
[24] J. Vincken,et al. Saponins, classification and occurrence in the plant kingdom. , 2007, Phytochemistry.
[25] M. Pescovitz. Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] L. Polito,et al. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine , 2004, Leukemia.
[27] I. Heisler,et al. A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins , 2003, International journal of cancer.
[28] K. Becker,et al. The biological action of saponins in animal systems: a review. , 2002, The British journal of nutrition.
[29] E. Vitetta,et al. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.
[30] F. Stivala,et al. Understanding rituximab function and resistance: implications for tailored therapy. , 2011, Frontiers in bioscience.